Format

Send to

Choose Destination
Cephalalgia. 2011 Apr;31(5):573-84. doi: 10.1177/0333102410388435. Epub 2010 Dec 20.

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study.

Author information

1
Department of Neurology and Headache Center, University Hospital Essen, University Duisburg-Essen, Hufelandstrasse 55, Essen, Germany. hans.diener@uni-duisburg-essen.de

Abstract

METHODS:

Four hundred and sixty-one adult subjects with migraine were randomised to one of five treatments, the oral antagonist at the calcitonin gene-related peptide (CGRP) receptor BI 44370 TA (50 mg, 200 mg, 400 mg), active comparator eletriptan 40 mg or placebo. The analysis included 341 subjects who took study medication.

RESULTS:

The primary endpoint, pain-free after two hours, was reached by significantly more subjects in the BI 44370 TA 400 mg (20/73 = 27.4%) and eletriptan 40 mg (24/69 = 34.8%) groups compared to placebo (6/70 = 8.6%, p = .0016), but not by subjects in the BI 44370 TA 200 mg group (14/65 = 21.5%). The effect of 50 mg BI 44370 TA (5/64 = 7.8%) was similar to that of placebo. Analysis of secondary endpoints supported the conclusion from the primary analysis. The frequency of adverse events was low in all groups.

CONCLUSION:

Efficacy of BI 44370 TA was shown in a dose-dependent manner in the treatment of acute migraine attacks.

PMID:
21172952
DOI:
10.1177/0333102410388435
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center